Windlas Biotech Ltd. (WINDLAS) AI Stock Analysis

• Market Cap: ₹16.96B
• Dividend Yield: 0.71%
• Average Volume (3M): 3.48K
• Price to Earnings (P/E): 27.9
• Beta (1Y): 0.86
• Revenue Growth: 19.34%
• EPS Growth: 9.32%
• Country: IN
• Employees: 1,154
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 7.12
• Shares Outstanding: 21,165,873
• 10 Day Avg. Volume: 3,282
• 30 Day Avg. Volume: 3,478
• PEG Ratio: 8.12
• Price to Book (P/B): 4.20
• Price to Sales (P/S): 2.80
• P/FCF Ratio: 132.80
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 71 Outperform
• Price Target: ₹815.00 ▲(3.42% Upside)
• Action: Upgraded Date: 01/15/26
• Date: Action: Upgraded 01/15/26

The score is primarily driven by strong financial performance (growth and profitability with low leverage), partially offset by mixed technicals (negative MACD and price below long-term moving averages) and a valuation profile that is not especially cheap with a low dividend yield.

Positive Factors

Sustained Revenue Growth

Consistent top-line expansion reflects durable demand for Windlas’s finished-dose and CDMO services. Revenue growth driven across periods supports scale economies, broader client engagement, and provides headroom to invest in capacity, R&D, and commercial reach over the next 2–6 months.

Negative Factors

Declining Operating Cash Flow

While cash generation remains positive, a YoY decline in operating cash flow and volatile free cash flow growth can constrain consistent funding for capex, working capital needs, or dividend increases. This volatility may limit strategic flexibility in the medium term.

Windlas Biotech Ltd. Business Overview & Revenue Model

Company Description

Windlas Biotech Limited operates as a contract development and manufacturing organization (CDMO). Its CDMO services include product discovery, product development, licensing, and commercial manufacturing generic products, including generic product...

Read more

Windlas Biotech Limited operates as a contract development and manufacturing organization (CDMO). Its CDMO services include product discovery, product development, licensing, and commercial manufacturing generic products, including generic product...

How the Company Makes Money

Windlas Biotech makes money primarily by manufacturing pharmaceutical finished-dosage formulations and supplying them to other pharmaceutical/healthcare companies under contract manufacturing and related arrangements. Under this model, customers (...

Read more

Windlas Biotech makes money primarily by manufacturing pharmaceutical finished-dosage formulations and supplying them to other pharmaceutical/healthcare companies under contract manufacturing and related arrangements. Under this model, customers (...

Windlas Biotech Ltd. Financial Statement Overview

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	8.30B	7.60B	6.29B	5.11B	4.63B	4.27B
Gross Profit	3.18B	2.88B	2.28B	1.81B	1.61B	1.52B
EBITDA	1.23B	1.12B	916.40M	701.91M	591.29M	361.68M
Net Income	673.21M	609.94M	581.87M	426.26M	380.89M	158.32M
Balance Sheet
Total Assets	8.14B	7.60B	6.26B	5.29B	4.91B	2.96B
Cash, Cash Equivalents and Short-Term Investments	2.61B	2.40B	2.04B	1.32B	1.76B	542.55M
Total Debt	312.09M	325.97M	36.41M	49.93M	66.37M	323.49M
Total Liabilities	2.80B	2.55B	1.76B	1.27B	962.33M	970.04M
Stockholders Equity	5.34B	5.06B	4.50B	4.02B	3.95B	1.99B
Cash Flow
Free Cash Flow	265.34M	159.93M	712.76M	-99.25M	-56.74M	56.07M
Operating Cash Flow	559.24M	681.87M	1.09B	609.65M	91.30M	114.54M
Investing Cash Flow	-437.62M	-740.64M	-920.68M	-141.10M	-1.55B	-201.98M
Financing Cash Flow	-123.71M	10.13M	-152.90M	-437.39M	1.30B	7.76M

Windlas Biotech Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 788.05
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:WINDLAS, the sentiment is Positive. The current price of 788.05 is above the 20-day moving average (MA) of 747.15, above the 50-day MA of 777.28, and below the 200-day MA of 864.36, indicating a neutral trend. The MACD of 1.89 indicates Negative momentum. The RSI at 57.94 is Neutral, neither overbought nor oversold. The STOCH value of 77.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:WINDLAS.

Windlas Biotech Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
WINDLAS	71 Outperform	₹16.96B	27.93	―	0.71%	19.34%	9.32%
SMSPHARMA	70 Outperform	₹38.91B	29.96	―	0.13%	11.91%	36.92%
SAKAR	66 Neutral	₹12.56B	22.21	―	―	24.20%	55.01%
BAJAJHCARE	53 Neutral	₹10.23B	20.91	―	0.24%	13.04%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
INDOCO	49 Neutral	₹18.51B	-18.14	―	0.08%	-2.81%	-444.69%

Windlas Biotech Ltd. Corporate Events